{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:38:14Z","timestamp":1792643894179,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.trsl.2026.10.007","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:28:58Z","timestamp":1792481338000},"page":"120-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Convergent ferroptosis and pyroptosis in MASLD-associated cardiac remodeling"],"prefix":"10.1016","volume":"298","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6992-8814","authenticated-orcid":false,"given":"Huayang","family":"Gui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.trsl.2026.10.007_bib0001","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.trsl.2026.10.007_bib0002","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S2468-1253(26)00011-7","article-title":"Global burden of metabolic dysfunction-associated steatotic liver disease, 1990-2023, and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2023","volume":"11","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.trsl.2026.10.007_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2024","journal-title":"Ann Hepatol"},{"issue":"4","key":"10.1016\/j.trsl.2026.10.007_bib0004","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.trsl.2026.10.007_bib0005","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41569-026-01257-z","article-title":"HFpEF and MASLD: converging mechanisms and clinical implications","volume":"23","author":"Capone","year":"2026","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.trsl.2026.10.007_bib0006","article-title":"Metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction: mechanisms and clinical implications from a heart-liver metabolic axis perspective","volume":"17","author":"Wu","year":"2026","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.trsl.2026.10.007_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2025.1573841","article-title":"Role of metabolic dysfunction-associated fatty liver disease in atrial fibrillation and heart failure: molecular and clinical aspects","volume":"12","author":"Cheung","year":"2025","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"10.1016\/j.trsl.2026.10.007_bib0008","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1002\/ejhf.70053","article-title":"Incidence of major cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease in the general population","volume":"27","author":"Huber","year":"2025","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10.1016\/j.trsl.2026.10.007_bib0009","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"issue":"20","key":"10.1016\/j.trsl.2026.10.007_bib0010","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.trsl.2026.10.007_bib0011","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41569-025-01199-y","article-title":"Cardiovascular\u2013kidney\u2013metabolic syndrome and MASLD: integrating medical perspectives","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"10.1016\/j.trsl.2026.10.007_bib0012","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1053\/j.gastro.2014.07.018","article-title":"Cell death and cell death responses in liver disease: mechanisms and clinical relevance","volume":"147","author":"Luedde","year":"2014","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.trsl.2026.10.007_bib0013","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1152\/physrev.00022.2018","article-title":"Fundamental mechanisms of regulated cell death and implications for heart disease","volume":"99","author":"Del Re","year":"2019","journal-title":"Physiol Rev"},{"issue":"6","key":"10.1016\/j.trsl.2026.10.007_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2026.101099","article-title":"Ferroptosis in MASLD: from molecular mechanisms to therapeutic opportunities","volume":"7","author":"Zhou","year":"2026","journal-title":"Med"},{"issue":"1","key":"10.1016\/j.trsl.2026.10.007_bib0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s43556-026-00420-9","article-title":"Ferroptosis in cardiovascular diseases: molecular mechanisms and a novel therapeutic target","volume":"7","author":"Yu","year":"2026","journal-title":"Mol Biomed"},{"key":"10.1016\/j.trsl.2026.10.007_bib0016","article-title":"Dual role of pyroptosis in liver diseases: mechanisms, implications, and therapeutic perspectives","volume":"13","author":"Yang","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.trsl.2026.10.007_bib0017","doi-asserted-by":"crossref","unstructured":"Wang L., Lu G., Xiang L., Fan Y., Liu K. The role of different types of programmed cell death in myocardial fibrosis: from mechanisms to therapeutics. Front. Cardiovasc. Med. 2026;13:1748166. doi:10.3389\/fcvm.2026.1748166.","DOI":"10.3389\/fcvm.2026.1748166"},{"issue":"4","key":"10.1016\/j.trsl.2026.10.007_bib0018","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.trsl.2026.10.007_bib0019","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","article-title":"Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease","volume":"171","author":"Stockwell","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2026.10.007_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1286449","article-title":"Metabolic dysfunction-associated steatotic liver disease: ferroptosis related mechanisms and potential drugs","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.trsl.2026.10.007_bib0021","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41569-022-00735-4","article-title":"The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease","volume":"20","author":"Fang","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"10.1016\/j.trsl.2026.10.007_bib0022","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000530046","article-title":"A panoramic view of ferroptosis in cardiovascular disease","volume":"9","author":"Cheng","year":"2023","journal-title":"Kidney Dis"},{"issue":"4","key":"10.1016\/j.trsl.2026.10.007_bib0023","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tibs.2022.10.002","article-title":"The NLRP3 inflammasome: activation and regulation","volume":"48","author":"Xu","year":"2023","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"10.1016\/j.trsl.2026.10.007_bib0024","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s11033-026-11960-2","article-title":"Targeting pyroptosis in metabolic dysfunction-associated steatotic liver disease: from molecular mechanisms to therapeutic innovation","volume":"53","author":"Li","year":"2026","journal-title":"Mol Biol Rep"},{"issue":"4","key":"10.1016\/j.trsl.2026.10.007_bib0025","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41569-023-00946-3","article-title":"The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases","volume":"21","author":"Toldo","year":"2024","journal-title":"Nat Rev Cardiol"},{"issue":"10","key":"10.1016\/j.trsl.2026.10.007_bib0026","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.3390\/ijms25105372","article-title":"The role of inflammasomes in heart failure","volume":"25","author":"Vlachakis","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.trsl.2026.10.007_bib0027","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41392-024-01962-6","article-title":"Characterization of ferroptosis-triggered pyroptotic signaling in heart failure","volume":"9","author":"Bi","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.trsl.2026.10.007_bib0028","article-title":"OxLDL-induced ferroptosis and pyroptosis in atherosclerosis: a mini review","volume":"17","author":"Liu","year":"2026","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2026.10.007_bib0029","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.71138","article-title":"The crosstalk mechanisms between ferroptosis and pyroptosis and their applications in diseases: from molecular networks to clinical strategies","volume":"30","author":"Zhao","year":"2026","journal-title":"J Cell Mol Med"},{"issue":"3","key":"10.1016\/j.trsl.2026.10.007_bib0030","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ"},{"issue":"6","key":"10.1016\/j.trsl.2026.10.007_bib0031","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41580-024-00703-5","article-title":"The cell biology of ferroptosis","volume":"25","author":"Dixon","year":"2024","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7784","key":"10.1016\/j.trsl.2026.10.007_bib0032","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41586-019-1705-2","article-title":"The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis","volume":"575","author":"Bersuker","year":"2019","journal-title":"Nature"},{"issue":"7860","key":"10.1016\/j.trsl.2026.10.007_bib0033","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41586-021-03539-7","article-title":"DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer","volume":"593","author":"Mao","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2026.10.007_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1469492","article-title":"Drivers of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: the threats of oxidative stress","volume":"11","author":"Minetti","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.trsl.2026.10.007_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101107","article-title":"NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis","volume":"23","author":"Dodson","year":"2019","journal-title":"Redox Biol"},{"issue":"15","key":"10.1016\/j.trsl.2026.10.007_bib0036","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.cca.2011.04.013","article-title":"The role of oxidative stress in non-alcoholic steatohepatitis","volume":"412","author":"Koek","year":"2011","journal-title":"Clin Chim Acta"},{"issue":"2","key":"10.1016\/j.trsl.2026.10.007_bib0037","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41419-020-2298-2","article-title":"Ferroptosis: past, present and future","volume":"11","author":"Li","year":"2020","journal-title":"Cell Death Dis"},{"issue":"11","key":"10.1016\/j.trsl.2026.10.007_bib0038","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3390\/antiox13111336","article-title":"Inhibiting ferroptosis prevents the progression of steatotic liver disease in obese mice","volume":"13","author":"Park","year":"2024","journal-title":"Antioxidants"},{"issue":"7","key":"10.1016\/j.trsl.2026.10.007_bib0039","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.trsl.2026.10.007_bib0040","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41569-023-00937-4","article-title":"Oxidized phospholipids in cardiovascular disease","volume":"21","author":"Tsimikas","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.trsl.2026.10.007_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/360438","article-title":"Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal","volume":"2014","author":"Ayala","year":"2014","journal-title":"Oxid Med Cell Longev"},{"issue":"9","key":"10.1016\/j.trsl.2026.10.007_bib0042","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrendo.2017.56","article-title":"Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance","volume":"13","author":"Meex","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"10.1016\/j.trsl.2026.10.007_bib0043","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1016\/j.bbagen.2012.09.008","article-title":"Glutathione synthesis","volume":"1830","author":"Lu","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.trsl.2026.10.007_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121873","article-title":"NSD2 promotes pressure overload-induced cardiac hypertrophy via activating circCmiss1\/TfR1\/ferroptosis signaling","volume":"328","author":"Xu","year":"2023","journal-title":"Life Sci"},{"issue":"6","key":"10.1016\/j.trsl.2026.10.007_bib0045","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00109-023-02318-3","article-title":"TRIM-containing 44 aggravates cardiac hypertrophy via TLR4\/NOX4-induced ferroptosis","volume":"101","author":"Wu","year":"2023","journal-title":"J Mol Med"},{"key":"10.1016\/j.trsl.2026.10.007_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177416","article-title":"Inhibition of ULK1 attenuates ferroptosis-mediated cardiac hypertrophy via HMGA2\/METTL14\/SLC7A11 axis in mice","volume":"995","author":"Zhang","year":"2025","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"10.1016\/j.trsl.2026.10.007_bib0047","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","article-title":"Cardiac energy metabolism in heart failure","volume":"128","author":"Lopaschuk","year":"2021","journal-title":"Circ Res"},{"issue":"8","key":"10.1016\/j.trsl.2026.10.007_bib0048","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41569-018-0044-6","article-title":"Metabolic remodelling in heart failure","volume":"15","author":"Bertero","year":"2018","journal-title":"Nat Rev Cardiol"},{"issue":"9","key":"10.1016\/j.trsl.2026.10.007_bib0049","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41569-022-00679-9","article-title":"Epicardial adipose tissue in contemporary cardiology","volume":"19","author":"Iacobellis","year":"2022","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"10.1016\/j.trsl.2026.10.007_bib0050","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1001\/2012.jama.11132","article-title":"Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults","volume":"308","author":"Neeland","year":"2012","journal-title":"JAMA J Am Med Assoc"},{"issue":"4","key":"10.1016\/j.trsl.2026.10.007_bib0051","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.tibs.2016.10.004","article-title":"Pyroptosis: gasdermin-mediated programmed necrotic cell death","volume":"42","author":"Shi","year":"2017","journal-title":"Trends Biochem Sci"},{"issue":"8","key":"10.1016\/j.trsl.2026.10.007_bib0052","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat Rev Immunol"},{"issue":"7575","key":"10.1016\/j.trsl.2026.10.007_bib0053","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/nature15541","article-title":"Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling","volume":"526","author":"Kayagaki","year":"2015","journal-title":"Nature"},{"issue":"7661","key":"10.1016\/j.trsl.2026.10.007_bib0054","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature22393","article-title":"Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin","volume":"547","author":"Wang","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.trsl.2026.10.007_bib0055","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/ni.2022","article-title":"Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling","volume":"12","author":"Wen","year":"2011","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/j.trsl.2026.10.007_bib0056","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1194\/jlr.M072454","article-title":"Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH","volume":"58","author":"Ioannou","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.trsl.2026.10.007_bib0057","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.2147\/JIR.S448723","article-title":"NcRNA regulated pyroptosis in liver diseases and traditional Chinese medicine intervention: a narrative review","volume":"Volume 17","author":"Deng","year":"2024","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.trsl.2026.10.007_bib0058","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.mam.2018.07.001","article-title":"Cardiac fibrosis: cell biological mechanisms, molecular pathways and therapeutic opportunities","volume":"65","author":"Frangogiannis","year":"2019","journal-title":"Mol Aspects Med"},{"issue":"7752","key":"10.1016\/j.trsl.2026.10.007_bib0059","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","article-title":"Nitrosative stress drives heart failure with preserved ejection fraction","volume":"568","author":"Schiattarella","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.trsl.2026.10.007_bib0060","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction","volume":"62","author":"Paulus","year":"2013","journal-title":"JACC"},{"issue":"1","key":"10.1016\/j.trsl.2026.10.007_bib0061","doi-asserted-by":"crossref","DOI":"10.1080\/10641963.2023.2189138","article-title":"GSDMD-mediated pyroptosis promotes cardiac remodeling in pressure overload","volume":"45","author":"You","year":"2023","journal-title":"Clin Exp Hypertens"},{"issue":"4","key":"10.1016\/j.trsl.2026.10.007_bib0062","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11897-017-0337-9","article-title":"Inflammation \u2013 Cause or consequence of heart failure or both?","volume":"14","author":"Van Linthout","year":"2017","journal-title":"Curr Heart Fail Rep"},{"issue":"5","key":"10.1016\/j.trsl.2026.10.007_bib0063","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.trsl.2026.10.007_bib0064","doi-asserted-by":"crossref","unstructured":"Liu Y., Liu C., Yin X., Yuan X. The integrative role of the microbiome in systemic immuno-inflammatory aberrations. Folia Microbiol. (Praha). Published online June 29, 2026. doi:10.1007\/s12223-026-01532-z.","DOI":"10.1007\/s12223-026-01532-z"},{"key":"10.1016\/j.trsl.2026.10.007_bib0065","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1038\/s41598-025-90667-z","article-title":"Metabolic dysfunction associated steatotic liver disease is associated with atrial fibrillation recurrence following cryoballoon ablation","volume":"15","author":"Wang","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.trsl.2026.10.007_bib0066","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41420-025-02372-5","article-title":"Different types of cell death and their interactions in myocardial ischemia\u2013reperfusion injury","volume":"11","author":"Du","year":"2025","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.trsl.2026.10.007_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2025.123565","article-title":"ROS-mediated ferroptosis and pyroptosis in cardiomyocytes: an update","volume":"370","author":"Li","year":"2025","journal-title":"Life Sci"},{"issue":"7717","key":"10.1016\/j.trsl.2026.10.007_bib0068","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41586-018-0372-z","article-title":"New mitochondrial DNA synthesis enables NLRP3 inflammasome activation","volume":"560","author":"Zhong","year":"2018","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.trsl.2026.10.007_bib0069","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.bbadis.2016.11.005","article-title":"Nrf2 signaling pathway: pivotal roles in inflammation","volume":"1863","author":"Ahmed","year":"2017","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"3","key":"10.1016\/j.trsl.2026.10.007_bib0070","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2018.06.083","article-title":"Mitochondrial dysfunction and signaling in chronic liver diseases","volume":"155","author":"Mansouri","year":"2018","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.trsl.2026.10.007_bib0071","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nri2975","article-title":"Mitochondria in innate immune responses","volume":"11","author":"West","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.trsl.2026.10.007_bib0072","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nrcardio.2016.203","article-title":"Mitochondrial function as a therapeutic target in heart failure","volume":"14","author":"Brown","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.trsl.2026.10.007_bib0073","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2025.1690411","article-title":"Gut microbiota on cardiovascular diseases-a mini review on current evidence","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Microbiol"},{"issue":"9","key":"10.1016\/j.trsl.2026.10.007_bib0074","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1111\/dom.16568","article-title":"Metabolic dysfunction-associated steatotic liver disease and sex-specific risk of fatal and non-fatal cardiovascular events: a meta-analysis","volume":"27","author":"Jamalinia","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.trsl.2026.10.007_bib0075","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3390\/ijtm4040052","article-title":"Contribution of sex differences to the development of cardiovascular disease in metabolic-associated steatotic liver disease (MASLD)","volume":"4","author":"Taylor","year":"2024","journal-title":"Int J Transl Med"},{"key":"10.1016\/j.trsl.2026.10.007_bib0076","doi-asserted-by":"crossref","DOI":"10.1186\/s13293-026-00952-3","article-title":"Sex differences in MASLD-related atherosclerosis: plaque phenotype, vascular dysfunction, and cardiovascular outcomes","volume":"17","author":"Jamalinia","year":"2026","journal-title":"Biol Sex Differ"},{"issue":"5","key":"10.1016\/j.trsl.2026.10.007_bib0077","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s10741-025-10528-9","article-title":"Sex differences in the presentation, pathophysiology, and prognosis of heart failure with preserved ejection fraction","volume":"30","author":"Ebong","year":"2025","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.trsl.2026.10.007_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102892","article-title":"Differences in hepatocellular iron metabolism underlie sexual dimorphism in hepatocyte ferroptosis","volume":"67","author":"Tao","year":"2023","journal-title":"Redox Biol"},{"issue":"7","key":"10.1016\/j.trsl.2026.10.007_bib0079","doi-asserted-by":"crossref","first-page":"267","DOI":"10.31083\/j.fbl2907267","article-title":"DHODH alleviates heart failure via the modulation of CoQ-related ferroptotic inhibition","volume":"29","author":"Wang","year":"2024","journal-title":"Front Biosci"},{"issue":"12","key":"10.1016\/j.trsl.2026.10.007_bib0080","first-page":"1844","article-title":"Sex-dependent mechanisms of cell death modalities in cardiovascular disease","volume":"38","author":"Horvath","year":"2022","journal-title":"Can J Cardiol"},{"issue":"5","key":"10.1016\/j.trsl.2026.10.007_bib0081","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/eurheartj\/ehx662","article-title":"Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: mendelian randomization and meta-analysis of 279\u2009013 individuals","volume":"39","author":"Lauridsen","year":"2018","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.trsl.2026.10.007_bib0082","article-title":"PNPLA3 polymorphisms and risk of hepatic and extrahepatic outcomes in MASLD: a meta-analysis of observational studies","volume":"8","author":"Celsa","year":"2026","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"3","key":"10.1016\/j.trsl.2026.10.007_bib0083","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/apt.70256","article-title":"Meta-analysis: effects of steatotic liver disease-associated genetic risk alleles on longitudinal outcomes","volume":"62","author":"Kubina","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.trsl.2026.10.007_bib0084","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.14309\/ajg.0000000000003169","article-title":"TM6SF2 -rs58542926 Genotype has opposing effects on incidence of hepatic and cardiac events in a community cohort","volume":"120","author":"Chen","year":"2025","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.trsl.2026.10.007_bib0085","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hep.31238","article-title":"Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population","volume":"72","author":"Gellert-Kristensen","year":"2020","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.trsl.2026.10.007_bib0086","first-page":"1955","article-title":"Genetic risk of fatty liver disease and mortality in the general population: a mendelian randomization study","volume":"43","author":"Gellert-Kristensen","year":"2023","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"1-2","key":"10.1016\/j.trsl.2026.10.007_bib0087","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","article-title":"Regulation of ferroptotic cancer cell death by GPX4","volume":"156","author":"Yang","year":"2014","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.trsl.2026.10.007_bib0088","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/clpt.2012.110","article-title":"Nrf2: a potential target for new therapeutics in liver disease","volume":"92","author":"Bataille","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.trsl.2026.10.007_bib0089","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12265-026-10793-5","article-title":"Targeting ferroptosis and pyroptosis in cardiovascular diseases: mechanisms and therapeutic implication","volume":"19","author":"Zhang","year":"2026","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.trsl.2026.10.007_bib0090","doi-asserted-by":"crossref","unstructured":"Tawfiq R.A., Attia Y.M., Sleem H.M., El-Sayed Ghoneim M. Disrupting cell death: ferroptosis and pyroptosis inhibition in hepatic ischemia-reperfusion injury via modulation of GPX4 and cGAS pathways by deferoxamine and octreotide. Front Pharmacol. 2025;16:1610718. doi:10.3389\/fphar.2025.1610718.","DOI":"10.3389\/fphar.2025.1610718"},{"issue":"15","key":"10.1016\/j.trsl.2026.10.007_bib0091","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/eurheartj\/ehq158","article-title":"Iron deficiency: an ominous sign in patients with systolic chronic heart failure","volume":"31","author":"Jankowska","year":"2010","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.trsl.2026.10.007_bib0092","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","article-title":"MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.trsl.2026.10.007_bib0093","article-title":"Pyroptosis in cardiovascular diseases: roles, mechanisms, and clinical implications","volume":"12","author":"Niu","year":"2025","journal-title":"Front Cardiovasc Med"},{"issue":"10","key":"10.1016\/j.trsl.2026.10.007_bib0094","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/s41419-021-04143-3","article-title":"Pyroptosis inhibition improves the symptom of acute myocardial infarction","volume":"12","author":"Liu","year":"2021","journal-title":"Cell Death Dis"},{"issue":"12","key":"10.1016\/j.trsl.2026.10.007_bib0095","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with Canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2026.10.007_bib0096","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12938-026-01554-1","article-title":"Salvigenin alleviates ferroptosis and pyroptosis in myocardial ischemia\/reperfusion models by inhibiting the NLRP3 pathway","volume":"25","author":"Su","year":"2026","journal-title":"Biomed Eng OnLine"},{"issue":"24","key":"10.1016\/j.trsl.2026.10.007_bib0097","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.trsl.2026.10.007_bib0098","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.trsl.2026.10.007_bib0099","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.trsl.2026.10.007_bib0100","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/metabo11030137","article-title":"Collection and storage of Human plasma for measurement of oxylipins","volume":"11","author":"Polinski","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.trsl.2026.10.007_bib0101","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.plefa.2019.09.001","article-title":"Temperature and time-dependent effects of delayed blood processing on oxylipin concentrations in human plasma","volume":"150","author":"Ramsden","year":"2019","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.trsl.2026.10.007_bib0102","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2147\/DMSO.S502336","article-title":"Pyroptosis-mediator GSDMD in plasma: a promising biomarker for early diagnosis of type 2 diabetes","volume":"Volume 18","author":"Huo","year":"2025","journal-title":"Diabetes Metab Syndr Obes Targets Ther"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524426002173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524426002173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:47:24Z","timestamp":1792640844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524426002173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":102,"alternative-id":["S1931524426002173"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2026.10.007","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Convergent ferroptosis and pyroptosis in MASLD-associated cardiac remodeling","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2026.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}